Related Experiment Video
Updated: Aug 20, 2025
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Latest updates on cellular and molecular biomarkers of gliomas
Maroun Bou Zerdan1, Ali Atoui2, Ali Hijazi2
1Department of Internal Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States.
Abstract:
Gliomas are the most common central nervous system malignancies, compromising almost 80% of all brain tumors and is associated with significant mortality. The classification of gliomas has shifted from basic histological perspective to one that is based on molecular biomarkers. Treatment of this type of tumors consists currently of surgery, chemotherapy and radiation therapy. During the past years, there was a limited development of effective glioma diagnostics and therapeutics due to multiple factors including the presence of blood-brain barrier and the heterogeneity of this type of tumors. Currently, it is necessary to highlight the advantage of molecular diagnosis of gliomas to develop patient targeted therapies based on multiple oncogenic pathway. In this review, we will evaluate the development of cellular and molecular biomarkers for the diagnosis of gliomas and the impact of these diagnostic tools for better tailored and targeted therapies.
Insights
Molecular biomarkers are revolutionizing brain tumor (glioma) diagnosis and treatment. Understanding these biomarkers enables targeted therapies for better patient outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Gliomas represent the most frequent central nervous system malignancies, accounting for nearly 80% of brain tumors.
- Significant mortality rates are associated with gliomas, necessitating advancements in diagnostics and therapeutics.
- Traditional histological classification is evolving towards molecular biomarker-based approaches.
Purpose of the Study:
- To review the evolution of cellular and molecular biomarkers for glioma diagnosis.
- To assess the impact of these biomarkers on developing tailored, targeted therapies for glioma patients.
Main Methods:
- Literature review focusing on advancements in glioma diagnostics.
- Analysis of molecular biomarker development and their therapeutic implications.
- Evaluation of challenges such as the blood-brain barrier and tumor heterogeneity.
Main Results:
- Molecular diagnosis offers significant advantages over traditional methods.
- Biomarker-driven approaches are crucial for personalized glioma treatment strategies.
- Targeted therapies show promise in overcoming limitations of current treatments.
Conclusions:
- The shift to molecular biomarkers is critical for improving glioma diagnosis and treatment.
- Patient-specific therapies based on molecular profiles can enhance treatment efficacy.
- Continued research into biomarkers will drive innovation in neuro-oncology.
